De-escalation and dose density in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line.

被引：0
|
作者：
Dennen, Syvart
Shao, Anran
Dennen, Syvart
Cockrum, Paul
Paluri, Ravi Kumar
机构：
[1] Genesis Res, Hoboken, NJ USA
[2] Ipsen Biopharmaceut Inc, Cambridge, MA USA
[3] Wake Forest Baptist Hlth, Winston Salem, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
130-544; 130-3426-5390-2622-5397; 613-135-244-3829-325-11291; 261-2394; 130-540-543-11341; 2; 1699; 239; 16; 193; 1692; 54; 1700; 8; 6; 4; 3;
D O I：
10.1200/JCO.2024.42.3_suppl.628
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：628 / 628
页数：1
相关论文
共 50 条
  • [21] NALIRIFOX Versus FOLFOX as First-oLine Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): Real-World Comparative Overall (OS) Survival Analysis
    O'Reilly, Eileen
    Li, Jia
    DerSarkissian, Maral
    Chang, Rose
    Cheng, Mu
    Yu, Louise
    Rane, Deepali
    Zhang, Li
    Xiao, Zhimin
    Benzaghou, Fawzi
    Duh, Mei Sheng
    Chen, Huanyu
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 176 - 176
  • [22] REAL-WORLD EXPERIENCE WITH TOFACITINIB DOSE DE-ESCALATION IN PATIENTS WITH MODERATE AND SEVERE ULCERATIVE COLITIS
    Yu, Amy
    Shi, Bingyan
    Ha, Nghiem
    Beck, Kendall
    GASTROENTEROLOGY, 2023, 164 (04) : S102 - S102
  • [23] Real-World Experience With Tofacitinib Dose De-Escalation in Patients With Moderate and Severe Ulcerative Colitis
    Yu, Amy
    Ha, Nghiem B.
    Shi, Bingyan
    Cheng, Yao-Wen
    Mahadevan, Uma
    Beck, Kendall R.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (12) : 3115 - +
  • [24] REAL-WORLD EXPERIENCE WITH TOFACITINIB DOSE DE-ESCALATION IN PATIENTS WITH MODERATE AND SEVERE ULCERATIVE COLITIS
    Yu, Amy
    Shi, Bingyan
    Ha, Nghiem
    Beck, Kendall
    INFLAMMATORY BOWEL DISEASES, 2023, 29 : S80 - S80
  • [25] Real-world overall survival of patients diagnosed with recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC).
    O'Reilly, Eileen Mary
    Yu, Kenneth H.
    Lamarre, Neil
    Surinach, Andy
    Cockrum, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma
    Yu, Kenneth H.
    Ozer, Muhammet
    Cockrum, Paul
    Surinach, Andy
    Wang, Shu
    Chu, Bong Chul
    CANCER MEDICINE, 2021, 10 (24): : 8934 - 8943
  • [27] REAL-WORLD CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH METASTATIC DUCTAL ADENOCARCINOMA (MPDAC) TREATED WITH LIPOSOMAL IRINOTECAN-BASED REGIMENS BY RACE
    Kim, G. P.
    Cockrum, P.
    Lamarre, N.
    Surinach, A.
    VALUE IN HEALTH, 2021, 24 : S23 - S23
  • [28] Real-world progression outcomes among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States
    Kim, G.
    Cockrum, P.
    Surinach, A.
    Wang, S.
    Lamarre, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S1092 - S1093
  • [29] Real-world evidence on long-term survivors of metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with liposomal irinotecan: NALLONG study
    Ueno, M.
    Yoo, C.
    Macarulla Mercade, T.
    Westphalen, C. B.
    Prager, G.
    Imaoka, H.
    Waldschmidt, D. T.
    Verslype, C.
    Okusaka, T.
    Ryoo, B-Y.
    Hedouin-Biville, F.
    Chevallier, B.
    van Laethem, J-L.
    ANNALS OF ONCOLOGY, 2024, 35 : S928 - S929
  • [30] Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan
    Koeller, Jim
    Surinach, Andy
    Arikian, Steven R.
    Zivkovic, Marko
    Janeczko, Patrick
    Cockrum, Paul
    Kim, George
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
12345